James Healy

Biography

Dr. James Healy joined Sofinnova in 2000 as a General Partner. He focuses on funding private and publicly traded bio-pharmaceutical companies. Dr. Healy has financed and served on the board of ten companies which received drug approvals from either the FDA or EMA. Dr. Healy represents Sofinnova on the board of directors of Amarin (AMRN), Ascendis (ASND), Auris (EARS), Coherus (CHRS), Edge (EDGE), Natera (NTRA), Iterum, Obseva, and Nucana. Previous investments and board memberships include Anthera Pharmaceuticals (ANTH), Cellective Therapeutics (acquired by AstraZeneca), CoTherix (CTRX, acquired by Actelion), Durata Therapeutics (DRTX, acquired by Actavis plc), InterMune (ITMN, acquired by Roche), Movetis (MOVE, acquired by Shire), Nextwave Pharmaceuticals (acquired by Pfizer), Novacea (NOVC, merged with Transcept), Preglem (acquired by Gideon Richter), Prestwick (acquired by Biovail), and Salveo Specialty Pharmacy (acquired by Catamaran). Prior to Sofinnova, Dr. Healy worked at Bayer (Miles) and Sanderling. In 2011, Dr. Healy won the IBF Risk Innovator Award and was named as one of the industry’s top leading Life Science investors in 2013 by Forbes Magazine. Dr. Healy has authored or co-authored thirteen peer reviewed articles and invited reviews, including three papers published in Nature. Dr. Healy received his MD and PhD in Immunology from Stanford University, through the NIH Medical Scientist Training Program. He was a Beckman Scholar, received a Novartis Bursary Award and performed neuroscience research at the University of Virginia. Dr. Healy graduated with a BA in Molecular Biology and a BA in Scandinavian Studies from the University of California at Berkeley where he graduated with Honors and received a Departmental Citation. Previously, Dr. Healy served as a member of the Executive Board of the College of Letters and Science at the University of California Berkley and has lectured on entrepreneurship at Stanford University. Dr. Healy currently is a Director on the Board of the National Venture Capital Association (NVCA) and the Board of the Biotechnology Industry Organization (BIO).

Research Interest

Medical Devices